RANCHO CUCAMONGA, Calif., March 26, 2018 -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO will be presenting at the Needham‘s 17th Annual Healthcare Conference on Wednesday, March 28, 2018 at 9:30 a.m. Eastern Time in New York, NY.
This presentation will be made available with a live webcast and may be accessed by visiting Amphastar Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.
About Amphastar:
Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company’s website at www.amphastar.com.
The Amphastar Pharmaceuticals’ logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene®, Amphadase® and Cortrosyn®, are the property of Amphastar Pharmaceuticals, Inc.
Forward-Looking Statement:
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, acquisitions and other matters related to its pipeline of product candidates, the timing for completion of construction at the Company’s IMS facility, its share buyback program and other future events. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission.
Contact:
William J. Peters
Chief Financial Officer
(909) 476-3416


BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 



